32
Participants
Start Date
January 31, 2012
Primary Completion Date
February 29, 2016
Study Completion Date
April 30, 2017
Panobinostat
"Panobinostat will be supplied as 5-mg or 20-mg pink/opaque-colored, hard gelatin capsules. Panobinostat is administered orally three times per week.~* Standard 3+3 design~* 3 out of 4 weeks"
Carfilzomib
"Carfilzomib in Cycle 1 will be initiated intravenously at 20 mg/m² on Days 1 and 2 and escalated to 27 mg/m² for Days 8, 9, 15, and 16 of Cycle 1 and for the duration of treatment.~* Standard 3+3 design~* Days 1/2, 8/9 and 15/16 every 4 weeks"
Dexamethasone
Dexamethasone (4 mg) must be given prior to each carfilzomib infusion during Cycle 1. Dexamethasone pre-dose should continue through Cycle 2 if fever is observed post-dose, Cycle 2 Day 1, or thereafter associated with the infusion of carfilzomib.
Emory University Winship Cancer Institute, Atlanta
University of Chicago, Chicago
UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco
Collaborators (3)
Emory University
OTHER
Multiple Myeloma Research Consortium
NETWORK
Novartis
INDUSTRY
Onyx Therapeutics, Inc.
INDUSTRY
Amgen
INDUSTRY
University of California, San Francisco
OTHER
University of Chicago
OTHER